Apr 01, 2019 / 11:00AM GMT
Operator
Dear ladies and gentlemen, welcome to the Merck investor and analyst conference call on FDA approves MAVENCLAD (cladribine) tablets as first and only short-course oral treatment for relapsing-remitting and active secondary progressive multiple sclerosis. (Operator Instructions) May I now hand you over to Constantin Fest, Head of Investor Relations, who will be -- lead you through this conference. Please go ahead, sir.
Constantin Fest - MERCK Kommanditgesellschaft auf Aktien - Head of IR
Many thanks, Anita. And a very warm welcome to this Merck conference call on the current news flow from our Healthcare business sector, the U.S. approval of MAVENCLAD. My name is Constantin Fest, Head of Investor Relations at Merck, and today, I'm joined in this call by Rehan Verjee, President of EMD Serono and Global Head of Innovative Medicine Franchises. Also joining us on this call are Luciano Rossetti, Global Head of Research and Development; as well as John Walsh, VP, Neurology, Immunology, U.S. Medical Affairs and Deputy CMO for North America.
During the next 30
Merck KGaA FDA Approval of MAVENCLAD Conference Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot